Genetic Diagnostic Laboratory 1

Услуги компании

Сфера деятельности

Our company is engaged in research on a commercial basis.We are interested in citizens with different races, rare DNA allows us to more fruitfully conduct research on human genetic modification using CRISPR-Cas9 technology.

Направления обучения

---

Dear friends, we are happy to answer You!



Experts of the Recombinant DNA Advisory Committee (RAC) approved the application of the University of Pennsylvania to conduct tests on human genetic modification using CRISPR-Cas9 technology . During the experiment, immune cells will be improved, which will effectively fight cancer.

Scientists are going to change several genes at once, which was not allowed by early methods of genome modification. Researchers will isolate immune system cells — T-lymphocytes-from cancer patients, which will then be implanted with neutralized viruses. The latter serve as a kind of transport for the delivery of the gene encoding the NY-ESO-1 protein receptor. This protein is often present on the surface of cancer cells, and almost never on the membrane of healthy ones.

CRISPR will also disrupt the PD-1 gene, which has been shown to weaken the activity of lymphocytes. The modified lymphocytes then return to the patient's body, where they begin to actively attack the tumor.

The two-year study will involve 156 people with different types of cancer: myeloma, sarcoma, and melanoma. Tumors must be resistant to existing treatments. As well as 1,500 people, donor patients who will participate in testing experiments on human genetic modification using CRISPR-Cas9 technology.

The recombinant DNA Advisory Committee is an organization within the U.S. Department of health that provides approval and recommendations for the development of methods for modifying or synthesizing DNA.Some of the members of the Commission, reviewing the application, expressed concern that the University of Pennsylvania has financial interests in the success of the experiment, because it has patents for the use of modified T-lymphocytes for the treatment of cancer. According to the experts, the University should accurately indicate its role in the study, whether it will simply supply immune cells or directly participate in the trials. In the end, the Committee unanimously approved the experiment.

In this regard, the leadership of the University of Pennsylvania decided to urgently invite donor patients on a voluntary commercial basis to participate in testing experiments on human genetic modification using CRISPR-Cas9 technology.